ABSTRACT
Melioidosis is an emerging infection with increasing endemic foci and global distribution. It is underrecognized and underdiagnosed because of factors including limited awareness of the disease, nonspecific clinical presentation, lack of diagnostic facilities in some locations, misidentification in laboratories inexperienced with culture, and identification of Burkholderia pseudomallei. Cutaneous findings are reported in approximately 10% to 20% of melioidosis cases and dermatologists may play a significant role in its recognition and management. The most dynamic situation of melioidosis recognition and/or expansion currently is in the United States. Global modeling had predicted that B. pseudomallei were potentially endemic in the southern United States and endemicity with local cases of melioidosis was confirmed in 2022. With the distribution and prevalence of melioidosis increasing globally and with this recent recognition that melioidosis is now endemic in the southern United States, it is important for dermatologists to maintain high clinical suspicion in appropriate patients and be familiar with its diagnosis and treatment. Here we review the available literature on cutaneous melioidosis to evaluate its epidemiology, etiology, pathophysiology and clinical presentation and provide guidance for diagnosis and management in dermatology practice.
Subject(s)
Burkholderia pseudomallei , Melioidosis , Humans , Melioidosis/diagnosis , Melioidosis/epidemiology , Melioidosis/drug therapy , Dermatologists , Risk FactorsABSTRACT
Rapid human-to-human transmission of monkeypox has created a public health emergency requiring prompt, multidisciplinary attention. Dermatologists are at the forefront of diagnosis due to the disease-defining skin lesions. Moreover, patients with pre-existing skin disease and those who are on immunosuppressive medications for skin disease may be at increased risk of severe infection. In this review, a panel of authors with expertise in complex medical dermatology and managing patients on immunosuppression reviews the literature and provides initial guidance for diagnosis and management in dermatology practices. Though there are knowledge gaps due to a lack of controlled studies, we support use of replication-deficit vaccines in all dermatologic patients who meet qualifying risk or exposure criteria. We offer strategies to optimize vaccine efficacy in patients with immunosuppression. We discuss alternative post-exposure treatments and their safety profiles. Finally, we outline supportive care recommendations for cutaneous manifestations of monkeypox. Large scale epidemiologic investigations and clinical trials will ultimately revise and extend our guidance.
Subject(s)
Dermatology , Mpox (monkeypox) , Skin Diseases , Humans , Mpox (monkeypox)/epidemiology , Vaccination , Disease Outbreaks , Skin Diseases/diagnosisSubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Mantle-Cell/diagnosis , Lymphoma, Mantle-Cell/drug therapy , Pruritus/etiology , Cytarabine/therapeutic use , Dexamethasone/therapeutic use , Disease Progression , Humans , Lymphoma, Mantle-Cell/complications , Male , Middle Aged , Oxaliplatin/therapeutic use , Rituximab/therapeutic useABSTRACT
The skin and bone marrow are two of the most dynamic organ systems of the human body. While the skin is only transiently involved in haematopoiesis in utero, cutaneous extramedullary haematopoiesis (CEMH) has been appreciated in various neonatal and adult diseases. The mechanism by which CEMH occurs remains poorly understood, but may be associated with the plasticity of blood and skin tissues. Extensive studies have documented expansion and differentiation of haematopoietic lineages from cutaneous tissues and vice versa. This review will discuss CEMH, potential mechanisms and laboratory findings that shed light on the interaction between both tissues. Further, we will discuss the implications of understanding the role of the skin in haematopoiesis, including the potential therapeutic function of manipulating either organ system in the treatment of pathologic processes in the other.
Subject(s)
Hematopoiesis, Extramedullary , Skin Diseases/etiology , Skin/cytology , Animals , Humans , Skin Diseases/therapyABSTRACT
Peripheral gamma-delta T-cell proliferations are encountered in reaction to certain infections and in primary malignancies. Identifying sources of benign reactions is key in avoiding unnecessary workup and surveillance of these aggressive malignancies. Borrelia infections have been implicated in a number of lymphoproliferative disorders, but rarely, if ever, in this setting. While gamma-delta T-cells are known to play a prominent role in the immune response to Borrelia infection, B-cell differentiation is encountered in the majority of Borrelia-associated proliferations. We present here a unique case of benign-appearing peripheral gamma-delta T-cell lymphoid proliferation in the setting of a tick-bite with subsequent erythema migrans-like skin findings.
Subject(s)
Bites and Stings/complications , Lyme Disease/complications , Lymphoproliferative Disorders/blood , Receptors, Antigen, T-Cell, gamma-delta/metabolism , T-Lymphocytes/metabolism , Ticks , Aged, 80 and over , Animals , Humans , Lymphoproliferative Disorders/microbiology , MaleABSTRACT
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN.
Subject(s)
Expert Testimony , Stevens-Johnson Syndrome/epidemiology , Aged , Child , Congresses as Topic , Early Diagnosis , Electronic Health Records , Female , Humans , Interdisciplinary Communication , Male , Pregnancy , Stevens-Johnson Syndrome/drug therapy , Stevens-Johnson Syndrome/immunology , Translational Research, Biomedical , United States/epidemiologyABSTRACT
BACKGROUND: Actinic keratosis is a precursor to cutaneous squamous cell carcinoma. Long treatment durations and severe side effects have limited the efficacy of current actinic keratosis treatments. Thymic stromal lymphopoietin (TSLP) is an epithelium-derived cytokine that induces a robust antitumor immunity in barrier-defective skin. Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis. METHODS: The mechanism of calcipotriol action against skin carcinogenesis was examined in genetically engineered mouse models. The efficacy and safety of 0.005% calcipotriol ointment combined with 5% 5-FU cream were compared with Vaseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-blind clinical trial involving 131 participants. The assigned treatment was self-applied to the entirety of the qualified anatomical sites (face, scalp, and upper extremities) twice daily for 4 consecutive days. The percentage of reduction in the number of actinic keratoses (primary outcome), local skin reactions, and immune activation parameters were assessed. RESULTS: Calcipotriol suppressed skin cancer development in mice in a TSLP-dependent manner. Four-day application of calcipotriol plus 5-FU versus Vaseline plus 5-FU led to an 87.8% versus 26.3% mean reduction in the number of actinic keratoses in participants (P < 0.0001). Importantly, calcipotriol plus 5-FU treatment induced TSLP, HLA class II, and natural killer cell group 2D (NKG2D) ligand expression in the lesional keratinocytes associated with a marked CD4+ T cell infiltration, which peaked on days 10-11 after treatment, without pain, crusting, or ulceration. CONCLUSION: Our findings demonstrate the synergistic effects of calcipotriol and 5-FU treatment in optimally activating a CD4+ T cell-mediated immunity against actinic keratoses and, potentially, cancers of the skin and other organs. TRIAL REGISTRATION: ClinicalTrials.gov NCT02019355. FUNDING: Not applicable (investigator-initiated clinical trial).
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma, Squamous Cell/drug therapy , Keratosis, Actinic/drug therapy , Precancerous Conditions/drug therapy , Skin Neoplasms/drug therapy , Administration, Topical , Aged , Aged, 80 and over , Animals , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , Calcitriol/administration & dosage , Calcitriol/analogs & derivatives , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/pathology , Cytokines/genetics , Cytokines/immunology , Female , Fluorouracil/administration & dosage , Humans , Immunity, Cellular/drug effects , Immunity, Cellular/genetics , Keratosis, Actinic/genetics , Keratosis, Actinic/immunology , Keratosis, Actinic/pathology , Male , Mice , Mice, Transgenic , Middle Aged , Precancerous Conditions/genetics , Precancerous Conditions/immunology , Precancerous Conditions/pathology , Skin Neoplasms/genetics , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Thymic Stromal LymphopoietinABSTRACT
Cutaneous leishmaniasis is a parasitic infection caused by protozoa of the Leishmania genus that presents as asymptomatic pink papules that may ulcerate. There are several species of Leishmania found in 98 endemic countries and whereas all are associated with cutaneous disease, only specific species can cause mucocutaneous or visceral disease. Although the diagnosis of cutaneous leishmaniasis can be confirmed with Giemsa staining of a biopsy or "touch prep" specimen, only speciation at specialized centers such as the Centers for Disease Control (CDC) can determine the risk of mucocutaneous or visceral disease. Treatment of cutaneous leishmaniasis is varied and depends on the extent of cutaneous disease and the risk of mucocutaneous or visceral disease.
Subject(s)
Leishmania mexicana , Leishmaniasis, Cutaneous/pathology , Leishmaniasis, Cutaneous/parasitology , Humans , Leishmaniasis, Cutaneous/therapy , Male , Mexico , Middle Aged , TravelABSTRACT
We present a case of a three-yr-old child with a history of multisystem Langerhans cell histiocytosis treated with systemic chemotherapy, who developed progressive liver failure and received an orthotopic split liver transplant while continuing on chemotherapy. One month following transplant, he developed acute graft-vs.-host disease of the skin and gastrointestinal tract. Peripheral blood chimerism studies post-transplant demonstrated an increasing predominance of donor lymphocytes and granulocytes. Shortly after, the patient developed vitiligo, and two yr after transplantation, the patient developed skin manifestations of psoriasis. We discuss and review the current literature, which demonstrates that chimerism following liver transplantation is rare and in our patient may be related to his profound immunosuppression around the time of liver transplant as well the development of acute graft-versus-host disease. While autoimmune disease can occur after solid organ and stem cell transplant, our patient developed skin manifestations of autoimmunity after liver transplantation, which is also rarely described.
Subject(s)
Bone Marrow/pathology , Graft vs Host Disease , Liver Transplantation/adverse effects , Skin Diseases/physiopathology , Autoimmunity , Biopsy , Child, Preschool , Gastrointestinal Tract/physiopathology , Granulocytes/cytology , Histiocytosis/physiopathology , Humans , Liver Transplantation/methods , Lymphocytes/cytology , Male , Postoperative Complications , Psoriasis/complications , Psoriasis/physiopathology , Transplantation Chimera , Vitiligo/complications , Vitiligo/physiopathologyABSTRACT
Sentinel lymph node biopsies are conducted to stage patients with newly diagnosed melanomas that have histopathological attributes conferring defined levels of metastatic potential. Because benign nevic cells may also form 'deposits' in lymph nodes (nodal nevus), the pathological evaluation for metastatic melanoma within sentinel lymph nodes can be challenging. Twenty-eight sentinel lymph node biopsy cases containing either metastatic melanoma (N=18) or nodal nevi (N=10) were retrieved from the archives of the Brigham and Women's Hospital, Department of Pathology (2011-2014). In addition, two sentinel lymph node cases that were favored to represent metastatic disease but whose histopathological features were viewed as equivocal, with melanoma favored, were also included. Dual labeling for the melanocyte lineage marker, MART-1, and the epigenetic marker, 5-hydroxymethylcytosine, a functionally significant indicator that has been shown to distinguish benign nevi from melanoma, was performed on all cases using immunohistochemistry and/or direct immunofluorescence. All (18 of 18) metastatic melanoma cases showed complete loss of 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells, and all (10 of 10) nodal nevus cases demonstrated 5-hydroxymethylcytosine nuclear staining in MART-1-positive cells. In addition, 5-hydroxymethylcytosine staining confirmed the favored diagnoses of metastatic melanoma in the two 'equivocal' cases. Thus, 5-hydroxymethylcytosine may be a useful adjunctive marker to distinguish between benign nodal nevi and metastatic melanoma during the evaluation of sentinel lymph node biopsies for metastatic melanoma.
Subject(s)
Cytosine/analogs & derivatives , Lymph Nodes/pathology , Lymphatic Metastasis/diagnosis , Melanoma/diagnosis , Nevus/diagnosis , Skin Neoplasms/diagnosis , 5-Methylcytosine/analogs & derivatives , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Cytosine/analysis , Cytosine/biosynthesis , Female , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Male , Middle Aged , Sentinel Lymph Node BiopsyABSTRACT
IMPORTANCE: Cutaneous sarcoidosis can present in pre-existing tattoos. Previous reports suggest modest improvement with systemic or topical corticosteroids or other immunomodulating medications. Tetracyclines have anti-inflammatory properties and have been shown to be efficacious in non-tattoo associated cutaneous sarcoidosis. The pharmacology of minocycline suggests that its higher concentration in the skin may improve its efficacy in the treatment of cutaneous granulomas. CASE REPORT: We present a case of a 35-year-old man with a history of pulmonary sarcoidosis who developed raised plaques within tattoos present for over 10 years. Skin biopsy findings revealed non-caseating granulomas consistent with cutaneous sarcoidosis. The patient was started on minocycline 100mg twice daily and had resolution of pruritus in four days and improvement of sarcoidal plaques within one week. CONCLUSIONS: To our knowledge, this is the first report of cutaneous sarcoidosis in tattoos treated with minocycline. Our patient's rapid response to minocycline suggests that minocycline may be a quickly effective medication for cutaneous sarcoidosis and should be considered as a therapeutic option given its favorable side-effect profile.
Subject(s)
Minocycline/therapeutic use , Sarcoidosis/drug therapy , Skin Diseases/drug therapy , Skin/pathology , Tattooing/adverse effects , Adult , Anti-Bacterial Agents/therapeutic use , Biopsy , Diagnosis, Differential , Humans , Male , Sarcoidosis/etiology , Sarcoidosis/pathology , Skin Diseases/etiology , Skin Diseases/pathologyABSTRACT
IMPORTANCE: Cryoglobulins are cold-precipitating immunoglobulins that occur secondary to lymphoproliferative disorders, chronic viral infections, and autoimmune disorders. The treatment of cryoglobulinemia should target the underlying disorder; however, such an approach may be difficult, and therapeutic options remain limited for type I cryoglobulinemia. OBSERVATIONS: We report a case of recalcitrant type I cryoglobulinemia treated successfully with long-term plasmapheresis in conjunction with thalidomide and dexamethasone. A woman in her 50s with cryoglobulinemia and bilateral lower extremity ulcers of 1 year's duration developed acute angle-closure glaucoma following the appearance of new macules on her upper extremities. An initial short course of 5 plasmapheresis treatments improved the patient's cutaneous lesions as well as the glaucoma. Three weekly doses of rituximab were not associated with any evidence of clinical improvement, so thalidomide and dexamethasone were administered as replacement therapy. Because of the increasing pain and persistence of the woman's ulcers, intensive plasmapheresis was resumed and continued 3 to 4 times per week for approximately 4 months, after which a slow tapering regimen was initiated. This therapy was associated with progressive, rapid healing of the ulcers, stabilization of the skin lesions, and control of the patient's intraocular pressure. CONCLUSIONS AND RELEVANCE: The long-term use of plasmapheresis may be a well-tolerated treatment option for therapeutically challenging cases of cryoglobulinemia.
Subject(s)
Cryoglobulinemia/therapy , Glaucoma, Neovascular/therapy , Plasmapheresis , Skin Ulcer/therapy , Angiogenesis Inhibitors/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Combined Modality Therapy , Dexamethasone/therapeutic use , Female , Humans , Middle Aged , Thalidomide/therapeutic use , Time FactorsABSTRACT
This series of 113 sequential biopsies of full facial transplants provides findings of potential translational significance as well as biological insights that could prompt reexamination of conventional paradigms of effector pathways in skin allograft rejection. Serial biopsies before, during, and after rejection episodes were evaluated for clinicopathological assessment that in selected cases included specific biomarkers for donor-versus-recipient T cells. Histologic evidence of rejection included lymphocyte-associated injury to epidermal rete ridges, follicular infundibula, and dermal microvessels. Surprisingly, during active rejection, immune cells spatially associated with target cell injury consisted abundantly or predominantly of lymphocytes of donor origin with an immunophenotype typical of the resident memory T-cell subset. Current dogma assumes that skin allograft rejection is mediated by recipient T cells that attack epidermal targets, and the association of donor T cells with sites of target cell injury raises questions regarding the potential complexity of immune cell interactions in the rejection process. A more histopathologically refined and immune-based biomarker approach to assessment of rejection of facial transplants is now indicated.
Subject(s)
Facial Transplantation/adverse effects , Graft Rejection/immunology , Graft vs Host Reaction/immunology , T-Lymphocytes/immunology , Adult , Allografts , Biomarkers/analysis , Fluorescent Antibody Technique , Humans , Immunohistochemistry , Middle Aged , Tissue DonorsABSTRACT
Two cases of a pseudoherpetic variant of Grover disease are presented. The first patient was a 60-year-old woman who had high fevers in combination with right lower lobe pneumonia. She developed an itchy papulovesicular rash on her back and upper abdomen. The second patient was a 68-year-old woman who while bedridden developed an itchy papulovesicular rash on her back. Vesiculobullous forms of dermatitis were clinically suspected in both cases, and herpetic vesicles were the lead diagnosis in one case. Pathologically, lesions from both patients revealed intraepidermal fluid-filled vesicles that at scanning magnification raised the suspicion of herpetic lesions. At higher magnification, acantholytic cells, some seemingly multinucleated, could be ppreciated. However, immunohistochemistry for herpes simplex virus and varicella zoster virus antigens proved negative. Moreover, some of the lesional cells revealed dyskeratosis more typical of the spongiotic/vesicular variant of Grover disease, and accordingly, this diagnosis was eventually established in both patients. Recognition of the pseudoherpetic variant of spongiotic/vesicular Grover disease is important in determining correct treatment, and therefore, subtle clues to its diagnosis should be sought in evaluation of such lesions.
Subject(s)
Acantholysis/pathology , Ichthyosis/pathology , Aged , Chickenpox/diagnosis , Diagnosis, Differential , Female , Humans , Middle AgedSubject(s)
Anus Neoplasms/therapy , Buschke-Lowenstein Tumor/therapy , Cytosine/analogs & derivatives , Interleukin-2/therapeutic use , Organophosphonates/therapeutic use , Administration, Topical , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , Anus Neoplasms/pathology , Buschke-Lowenstein Tumor/pathology , Cidofovir , Combined Modality Therapy , Cytosine/administration & dosage , Cytosine/therapeutic use , Drug Therapy, Combination , Follow-Up Studies , Humans , Immunocompromised Host , Interleukin-2/administration & dosage , Male , Middle Aged , Neoplasm Recurrence, Local , Organophosphonates/administration & dosage , Treatment OutcomeABSTRACT
CONTEXT: Wolf isotopic response has infrequently been reported in the literature, mainly as isolated case reports. OBJECTIVE: To aid in recognition of the occurrence of postherpetic granuloma annulare for accurate histologic interpretation of granulomatous dermatitides. DESIGN: We report 5 cases of patients with Wolf isotopic response manifesting as granuloma annulare, developing in a site of previous herpes zoster, and discuss the clinicopathologic findings. RESULTS: Previous infection with herpes zoster or herpes simplex virus was found in 5 of 5 cases reported. The differential diagnosis of a dermal lymphohistiocytic infiltrate with multinucleated giant cells includes postherpetic granuloma annulare. CONCLUSIONS: All cases of postherpetic Wolf isotopic response reported in this series revealed granuloma annulare, with a perineurovascular or perifollicular pattern of lymphohistiocytic infiltration including multinucleated giant cells, and occurred following herpes zoster or herpes simplex infection, although herpes viral infection was not always associated with a subsequent isotopic eruption. Awareness of this entity can aid in the clinicopathologic diagnosis of granuloma annulare occurring at the site of prior herpes viral infection.
Subject(s)
Granuloma Annulare/diagnosis , Granuloma Annulare/etiology , Herpes Zoster/complications , Diagnosis, Differential , Female , Giant Cells/pathology , Granuloma Annulare/pathology , Histiocytes/pathology , Humans , Male , Middle Aged , Skin/pathologyABSTRACT
OBJECTIVE: We have studied dense erythrocytes separated on Arabinogalactan (Stractan) ultracentrifuged gradients in flame-burned patients and in normal individuals. In each case, the percentage of erythrocytes in the densest layers was increased when compared to age and sex matched controls. METHODS AND RESULTS: Using an in vitro system, we showed that as human whole blood is warmed to 48.6°C, the number of dense erythrocytes increases. In addition, the reduced glutathionine (GSH) content of the densest red blood cells is decreased compared to those in lighter fractions on the same gradient or to dense erythrocytes separated from blood incubated at room temperature. These dense red cells were largely composed of spherocytes and spheroechynocytes, two forms of erythrocytes which have been shown by others to have markedly abnormal flow characteristics in vitro. CONCLUSIONS: We have demonstrated that in vivo dense erythrocytes can be generated in the setting of flame burns. Thus, the underlying reason may be oxidant injury as represented by the reduced level of GSH that we found in association with the generation of dense erythrocytes.